Effects of SR 141716A after acute or chronic cannabinoid administration in dogs

European Journal of Pharmacology

Volumn 357, Issue 2-3, 1998, Pages 139-148

  Lichtman, Aron H ^a   Wiley, Jenny L ^a   Lavecchia, Kari L ^a   Neviaser, Scott T ^a   Arthur, David B ^a   Wilson, David M ^a   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

9 Tetrahydrocannabinol; Anandamide; Cannabinoid; Dependence; SR 141716A; Static ataxia; Withdrawal precipitated

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BEHAVIOR; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WITHDRAWAL SYNDROME;

ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; CANNABINOIDS; DOGS; FEMALE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 0032544775     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00558-5     Document Type: Article

References (57)

1. Aceto M.D., Scates S.M., Lowe J.A., Martin B.R. Cannabinoid precipitated withdrawal by the selective cannabinoid antagonist, SR 141716A. Eur. J. Pharmacol. 282:1995;R1-R2.
2. 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J. Pharmacol. Exp. Ther. 278:1996;1290-1295.
3. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
4. Beardsley P.M., Balster R.L., Harris L.S. Dependence on tetrahydrocannabinol in rhesus monkeys. J. Pharmacol. Exp. Ther. 239:1986;311-319.
5. Brodkin J., Moerschbaecher J.M. SR 141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J. Pharmacol. Exp. Ther. 282:1997;1526-1532.
6. Burkey R.T., Nation J.R. (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure. Exp. Clin. Psychopharmacol. 5:1997;195-202.
7. 1 receptor agonists in the mouse brain. Eur. J. Pharmacol. 336:1997;295-298.
8. Campbell, W.B., Halushka, P.V., 1996. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill, New York, NY, pp. 601-616.
9. Chen K., Kandel D.B., Davies M. Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. Drug Alcohol Depend. 46:1997;53-67.
10. Childers S.R., Sexton T., Roy M.B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochemical Pharmacology. 47:1994;711-715.
11. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
12. 9-THC. J. Pharmacol. Ther. Exp. 285:1998;1150-1156.
13. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
14. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
15. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
16. 9-tetrahydrocannabinol on behavior and the cardiovascular system of dogs. Arch. Int. Pharmacodyn. 198:1972;118-131.
17. DSM-IV, 1994. Cannabis Dependence. In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV, American Psychiatric Association, Washington, DC, p. 216.
18. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
19. Johnston, L.D., O'Malley, P.M., Bachman, J.G., 1995. National Survey Results on Drug Use from the Monitoring the Future Study, Vol. 1, 1975-1994. U.S. Department of Health and Human Services, Washington, DC.
20. Jones, R.T., Benowitz, N., 1976. The 30-day trip-clinical studies of cannabis tolerance and dependence. In: Braude, M.C., Szara, S. (Eds.), Pharmacology of Marihuana, Vol. 2, Raven Press, New York, pp. 627-642.
21. Jones R.T., Benowitz N.L., Herning R.I. Clinical relevance of cannabis tolerance and dependence. J. Clin. Pharmacol. 21:1981;143S-152S.
22. 9-tetrahydrocannabinol. Acta. Medica. Turcica. Suppl. 1:1972;5.
23. 1 receptor. Eur. J. Pharmacol. 331:1997;R1-R2.
24. Lake K.D., Martin B.R., Kunos G., Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension. 29:1997;1204-1210.
25. Leff P., Scaramellini C., Law C., McKechnie K. A three-state receptor model of agonist action. Trends Pharmacol. Sci. 18:1997;355-362.
26. Leite J.R., Carlini E.A. Failure to obtain 'cannabis-directed behavior' and abstinence syndrome in rats chronically treated with cannabis sativa extracts. Psychopharmacologia. 36:1974;133-145.
27. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
28. Lichtman A.H., Martin B.R. The selective cannabinoid antagonist, SR 141716A, blocks cannabinoid-induced antinociception in rats. Pharmacol. Biochem. Behav. 57:1997;7-12.
29. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacol. 119:1995;282-290.
30. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
31. 8-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 32:1989;661-666.
32. Mackie K., Devane W., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
33. Mallet P.E., Beninger R.J. The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav. Pharmacol. 7:1996;276-284.
34. 9-Tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs J. Pharmacol. Exp. Ther. 196:1976;128-144.
35. 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity. Pharmacol. Biochem. Behav. 21:1984;61-65.
36. Marzo V.D., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
37. McMillan D.E., Dewey W.L., Harris L.S. Characteristics of tetrahydrocannabinol tolerance. Ann. N.Y. Acad. Sci. 191:1971;83-99.
38. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38:1986;75-149.
39. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.C., Le Fur G. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
40. Rodriguez de Fonseca F., Carrera M.R.A., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
41. 2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
42. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
43. 9-tetrahydrocannabinol-induced antinociception in mice without altering other pharmacological effects. J. Pharmacol. Exp. Ther. 268:1994;1381-1387.
44. Terranova J.-P., Michaud J.-C., Le Fur G., Soubrie P. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN 55212-2: Reversal by SR 141716A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;576-579.
45. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280:1995;R13-R15.
46. Varga K., Lake K., Martin B., Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278:1995;279-283.
47. Vogel Z., Berg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
48. Walton R.P., Martin L.F., Keller J.H. The relative activity of various purified products obtained from American grown hashish. J. Pharmacol. Exp. Ther. 62:1938;239-251.
49. 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273:1995;1235-1244.
50. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
51. Wiley J., Balster R.L., Martin B. Discriminative stimulus effects of anandamide in rats. Eur. J. Pharmacol. 276:1995;49-54.
52. Wiley J., Barrett R., Lowe J., Balster R., Martin B. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:1995;669-676.
53. 9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995;1-6.
54. 9-THC-trained rhesus monkeys. Pharmacol. Biochem. Behav. 58:1997;1139-1143.
55. Willoughby K.A., Moore S.F., Martin B.R., Ellis E.F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282:1997;243-247.
56. 8-Tetrahydrocannabinol, a cannabinoid of metabolic interest. J. Med. Chem. 17:1974;475-476.
57. Wilson R.S., May E.L. Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties. J. Med. Chem. 22:1979;886-888.